Leadership & Pay ·
Citius Oncology, Inc. announced the appointment of Jonathan Peri, Ph.D., J.D., as an independent Class I director to…
CTORCitius Oncology, Inc.
Citius Oncology, Inc. announced the appointment of Jonathan Peri, Ph.D., J.D., as an independent Class I director to its Board of Directors, effective August 10, 2026. The Board expanded from eight to nine members following a unanimous vote by the Corporate Governance and Nominating Committee. Dr. Peri currently serves as President of Manor College and previously held leadership roles at Neumann University and First State Bank. He brings expertise in higher education administration, legal counsel, and corporate governance. Citius Oncology is an oncology-focused biopharmaceutical company developing and commercializing targeted therapies for cutaneous T-cell lymphoma.